bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
Portfolio Pulse from
bluebird bio has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outcomes-based agreement for its LYFGENIA gene therapy under the Cell and Gene Therapy Access Model. LYFGENIA is approved for treating sickle cell disease in patients 12 years and older.
December 04, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
bluebird bio has partnered with the Center for Medicare and Medicaid Innovation to provide LYFGENIA gene therapy under an outcomes-based agreement, potentially increasing access and adoption.
The partnership with CMMI for an outcomes-based agreement could enhance the adoption of LYFGENIA, potentially leading to increased revenues for bluebird bio. This agreement may also improve the company's reputation in the healthcare sector.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90